news
IMU-838 shows some clinical benefit in moderate COVID-19 patients
The oral treatment slightly shortened time to clinical improvement and recovery in a Phase II trial, with greatest benefits in high-risk and elderly COVID-19 patients.
List view / Grid view
Therapeutics
news
Marketing of Zynteglo suspended as precaution due to potential cancer risk
bluebird bio has chosen to suspend sales of Zynteglo while they investigate whether safety concerns identified with a related investigational gene therapy may apply to the licenced medicine.
article
The current and future landscape of HIV treatments and vaccines
Dr Caroline Forkin from ICON discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
article
Biosimilar uptake: a clinician’s perspective
To ensure that clinicians buy into biosimilars, it is important that they understand how products are analysed and compared to the originator molecules. Dr Fraser Cummings and Jonathan Sweeting discussed this issue at a recent virtual roundtable event, where they highlighted the complexities of biosimilar development pathways and approval processes. Here, Nikki Withers shares the…
article
Manufacturing of CAR T-cell therapies: an overview
The emergence of CAR T-cell therapies has ignited a revolution in the field of cancer treatments. While existing products show outstanding curative capability, they are hampered by significant clinical and commercial challenges, many of which stem from their manufacturing process. Maciej Nakoniecznik discusses how a combination of biological and technological advances…
article
Sourcing of active pharmaceutical ingredients
Considerations when sourcing active pharmaceutical ingredients (APIs) can often be condensed to ones of economy and purity. Here, Dave Elder highlights the importance of defining those attributes that impact final product quality to ensure pharma companies find the best ingredient suppliers.
news
Chemspec Europe 2021 postponed
The 35th International Exhibition for Fine and Speciality Chemicals will now take place as live and digital hybrid event from 29 to 30 September 2021.
article
Bioprocessing & Bioproduction In-Depth Focus 2021
In this in-depth focus, discover how biological and technological advances could enhance the clinical capabilities of CAR T-cell therapies and explore why clinicians need to be better educated about the development and licencing of biosimilars.
news
EC approves first high concentration, low-volume adalimumab biosimilar
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
news
February Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began two new reviews and wrote guidance for healthcare professionals on the potential side effects of Strimvelis, Venclyxto and Zolgensma.
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine-300x278.jpg)
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine.jpg)
news
Therapeutic proteins and oral vaccines market to surpass $300,000mn by 2027
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
article
Microbiome therapeutic development boosted by metabolomics
There is a growing adoption of metabolomics to support drug discovery and development. Metabolomics involves the comprehensive analysis of metabolites in biological specimens. As such, it is commonly used for the discovery and validation of biomarkers that can support critical decisions in the drug development process. In this article, Christopher…
news
EC approves Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia
The approval makes Ogluo™ Europe’s first ready-to-use liquid glucagon for rescuing diabetic patients from severe hypoglycaemic events.
news
Semaglutide: “a significant advance in the treatment of obesity,” say scientists
After 75 percent of obese patients treated with semaglutide lost at least 10 percent of their body weight, the drug has been submitted for regulatory approval in the UK, Europe and US.
news
Zyesami™ shows promise in critical COVID-19 patients with respiratory failure
Preliminary data indicate that Zyesami reduces the length of hospital stay in critical COVID-19 patients treated with High Flow Nasal Cannula (HFNC) therapy or mechanical ventilation.
